Difference between revisions of "Team:Sydney Australia/Applied Design"

Line 400: Line 400:
 
<div class = "box1">
 
<div class = "box1">
 
</div>
 
</div>
−
</div>
 
−
 
 
<center><h4>The price of insulin is too high for many across the globe.  For type I diabetics, who must take insulin every day to survive, and roughly 30% of type II diabetics, this issue constrains their quality of life. Worse still, diagnosis of diabetes is on the rise. <br>
 
<center><h4>The price of insulin is too high for many across the globe.  For type I diabetics, who must take insulin every day to survive, and roughly 30% of type II diabetics, this issue constrains their quality of life. Worse still, diagnosis of diabetes is on the rise. <br>
 
Currently 92% of the insulin market is produced by 3 pharmaceutical companies. In economics, this kind of market share is called an oligopoly. In these kinds of markets, generic or biosimilar insulins have a hard time breaking through, simply due to the enormity of market share that the other three own. <br>
 
Currently 92% of the insulin market is produced by 3 pharmaceutical companies. In economics, this kind of market share is called an oligopoly. In these kinds of markets, generic or biosimilar insulins have a hard time breaking through, simply due to the enormity of market share that the other three own. <br>
 
To make things just a little more difficult, clinical trial expenses and regulatory licensing means that very few small to medium sized manufacturing plants can enter the market. Because of these constraints, the insulin market is spiraled out, and as such, is largely unaffordable and inaccessible across the board.</h4></center>
 
To make things just a little more difficult, clinical trial expenses and regulatory licensing means that very few small to medium sized manufacturing plants can enter the market. Because of these constraints, the insulin market is spiraled out, and as such, is largely unaffordable and inaccessible across the board.</h4></center>
 +
 +
</div>
 +
  
 
{{:Team:Sydney_Australia/templates/barriers}}
 
{{:Team:Sydney_Australia/templates/barriers}}

Revision as of 00:15, 29 October 2017

The Issue

The price of insulin is too high for many across the globe. For type I diabetics, who must take insulin every day to survive, and roughly 30% of type II diabetics, this issue constrains their quality of life. Worse still, diagnosis of diabetes is on the rise.
Currently 92% of the insulin market is produced by 3 pharmaceutical companies. In economics, this kind of market share is called an oligopoly. In these kinds of markets, generic or biosimilar insulins have a hard time breaking through, simply due to the enormity of market share that the other three own.
To make things just a little more difficult, clinical trial expenses and regulatory licensing means that very few small to medium sized manufacturing plants can enter the market. Because of these constraints, the insulin market is spiraled out, and as such, is largely unaffordable and inaccessible across the board.

{{:Team:Sydney_Australia/templates/barriers}}

Potential Solutions



1. PUBLIC TRADING SCHEME
2. OPEN-SOURCE INSULIN PUMP
3. STANDARD BUSINESS MODEL
4. PRIVATE INVESTMENT
5. BATHTUB INSULIN
6. PUBLIC INVESTMENT
7. GENE THERAPY
8. GUT BACTERIA INSULIN
9. ANIMAL
INSULIN
10.BLACK MARKET
INSULIN

Find out More Info About these Solutions By Clicking on Their Box!

1. Public Trading Scheme

BACKGROUND


ISSUES







stuff

2. Open-Source Insulin Pump / Cloud Monitoring

3. Standart Business Model

4. Private Investment

5. Bathtub Insulin

6. Public Investment

7. Gene Therapy

8. Gut Bacteria Insulin Secretion

9. Animal Insulin

10. Black Market Insulin

Our Solution

Making Biosynthetic Bacteria Open Source!